ClinicalTrials.gg
CompletedNCT02598583Updated May 16, 2022Results posted

Dose-Escalation Study of ALXN1210 IV in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

A Phase 1/2 interventional study of ALXN1210 in PNH, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 8 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-16.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
13
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 35 studies in Hemoglobinuria, Paroxysmal by AstraZeneca — 3 open to participants now, 7 under way, 2 of them phase 3. Hemoglobinuria, Paroxysmal · AstraZeneca.

Enrollment
16th of 23
13 · median 26
Started
2015
the only one that year
Phase 1/2
Only one
of the 35
Registered
12th of 35
by date

Among the 35 studies in Hemoglobinuria, Paroxysmal by AstraZeneca, this one is the 16th largest by enrollment of the 23 interventional ones that give a count, is the only one that started in 2015, is the only one in phase 1/2, and was the 12th registered.

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.

Browse Hemoglobinuria, Paroxysmal studies →

Open to participants now

3 of the 35 studies in Hemoglobinuria, Paroxysmal by AstraZeneca are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Hemoglobinuria, Paroxysmal by AstraZeneca, or all of them as a file.
02

Study summary

This study evaluated the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of multiple intravenous (IV) doses of ALXN1210 administered to participants with PNH who have not previously been treated with complement inhibitor.

Read the detailed description

The data presented is up to the Primary Completion date of the study and is for the 24-week Primary Evaluation period. The study also includes an Extension Period of up to 5 years.

03

Conditions studied

  • PNH

Keywords

  • Paroxysmal Nocturnal Hemoglobinuria
  • PNH
  • complement inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female ≥18 years of age
  2. PNH diagnosis confirmed by documented high-sensitivity flow cytometry
  3. Documented meningococcal vaccination not more than 3 years prior to dosing
  4. Female participants of used highly effective starting at screening and continuing until at least 24-weeks after the last dose of ALXN1210
  5. Willing and able to give written and comply with the study visit schedule

Exclusion criteria

Exclusion Criteria:

  1. Treatment with a complement inhibitor at any time
  2. Females who were pregnant, breastfeeding or who had a positive pregnancy test at screening or Day 1
  3. Participation in an interventional clinical study within 30 days before initiation of dosing on Day 1, or use of any experimental therapy within 30 days prior to dosing on Day 1, or within 5 half-lives of the product, whichever is greater
  4. History of allergy to of ALXN1210 or known allergy to Chinese hamster ovary cell proteins
  5. Inability to comply with study requirements
  6. History of any cardiac, hepatic, immunologic, pulmonary, or rheumatoid disease that, in the Investigator's judgment, would preclude participation
  7. Other unspecified reasons that, in the opinion of the Investigator or Sponsor, made the participant unsuitable for enrollment
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Participants were administered ALXN1210 900 mg. In the Extension period participants continued at the same dose and frequency as the Primary Evaluation Period.

    Biological: ALXN1210

  • Experimental
    Cohort 2

    Participants were administered ALXN1210 1800 mg. In the Extension period participants continued at the same dose and frequency as the Primary Evaluation Period.

    Biological: ALXN1210

Interventions

  • BiologicalALXN1210

    Participants were administered ravulizumab as an IV infusion every 4 weeks.

06

What researchers measure

Primary outcomes

  1. Percent Change In Lactate Dehydrogenase (LDH) Levels From Baseline To Day 169

    Baseline was defined as the average of all available assessments prior to first ALXN1210 infusion.

    Time frame: Baseline, Day 169

Secondary outcomes

  1. Percent Change In Free Hemoglobin Levels From Baseline To Day 169 And Day 1821

    Baseline was defined as the last non-missing assessment value prior to the first ALXN1210 infusion.

    Time frame: Baseline, Day 169, Day 1821

  2. Percent Change In Haptoglobin Levels From Baseline To Day 169 And Day 1821

    Baseline was defined as the last non-missing assessment value prior to the first ALXN1210 infusion.

    Time frame: Baseline, Day 169, Day 1821

  3. Percent Change In Reticulocyte/Erythrocyte Count From Baseline To Day 169 And Day 1821

    Baseline was defined as the last non-missing assessment value prior to the first ALXN1210 infusion.

    Time frame: Baseline, Day 169, Day 1821

  4. Percent Change In Paroxysmal Nocturnal Hemoglobinuria (PNH) Red Blood Cell (RBC) Clones From Baseline To Day 169 And Day 1933

    Baseline was defined as the last non-missing assessment value prior to the first ALXN1210 infusion.

    Time frame: Baseline, Day 169, Day 1933

  5. Percent Change In D-dimer Levels From Baseline To Day 169 And Day 1821

    Baseline was defined as the last non-missing assessment value prior to the first ALXN1210 infusion.

    Time frame: Baseline, Day 169, Day 1821

  6. Change In Clinical Manifestations Of PNH From Baseline To Day 169 And Day 1821

    Clinical manifestations are defined as fatigue, abdominal pain, dyspnea, dysphagia, chest pain, and erectile dysfunction (ED) by cohort. Improvement is defined as present at baseline and absent at Day 169 endpoint. Worsening is defined as absent at Baseline and present at Day 169 endpoint.

    Time frame: Baseline, Day 169, Day 1821

  7. Area Under The Serum Concentration-versus-time-curve From Time 0 (Dosing) To The Last Quantifiable Concentration (AUCt) At Day 1

    AUCt reported in hours\*microgram/milliliter (h\*ug/mL).

    Time frame: Day 1

  8. AUCt/ Dose-normalized (D) At Day 1

    Time frame: Day 1

  9. Area Under The Serum Concentration-versus-time-curve From Time 0 (Dosing) To The End Of The Dosing Interval (AUCtau) At Day 141

    Time frame: Day 141

  10. AUCtau/D At Day 141

    Time frame: Day 141

  11. Maximum Observed Serum Concentration (Cmax) At Day 1 And Day 141

    Time frame: Day 1 and Day 141

  12. Cmax/D At Day 1 And Day 141

    Time frame: Day 1 and Day 141

  13. Concentration At The End Of The Dosage Interval (Ctrough) At Day 1 And At Day 141

    Time frame: Day 1 and Day 141

  14. Time To Maximum Observed Serum Concentration (Tmax) At Day 1 And Day 141

    Time frame: Day 1 and Day 141

  15. Percent Change In Chicken Red Blood Cell (cRBC) Hemolysis From Baseline To Day 1709

    Time frame: Baseline, Day 1709

  16. Percent Change In Free Complement Component 5 (C5) Concentration From Baseline To Day 1709

    Time frame: Baseline, Day 1709

  17. Percent Change In Total C5 Concentration From Baseline To Day 1709

    Time frame: Baseline, Day 1709

  18. Participants Experiencing Antidrug Antibodies (ADAs)

    Time frame: Day 1821

07

Results

Posted Jan 30, 2018

Participant flow

Primary Evaluation Period
Participant flow — Primary Evaluation Period
MilestoneALXN1210 Cohort 1ALXN1210 Cohort 2
Started67
Completed67
Not completed00
Extension Period
Participant flow — Extension Period
MilestoneALXN1210 Cohort 1ALXN1210 Cohort 2
Started67
Completed57
Not completed10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryPercent Change In Lactate Dehydrogenase (LDH) Levels From Baseline To Day 169

Baseline was defined as the average of all available assessments prior to first ALXN1210 infusion.

Time frame:
Baseline, Day 169
Reported as:
Mean · percent change
Percent Change In Lactate Dehydrogenase (LDH) Levels From Baseline To Day 169
percent changeALXN1210 Cohort 1ALXN1210 Cohort 2
Percent Change In Lactate Dehydrogenase (LDH) Levels From Baseline To Day 169-85.952 ± 3.1897-84.736 ± 3.7736
SecondaryPercent Change In Free Hemoglobin Levels From Baseline To Day 169 And Day 1821

Baseline was defined as the last non-missing assessment value prior to the first ALXN1210 infusion.

Time frame:
Baseline, Day 169, Day 1821
Reported as:
Mean · percent change
Percent Change In Free Hemoglobin Levels From Baseline To Day 169 And Day 1821
percent changeALXN1210 Cohort 1ALXN1210 Cohort 2
Day 169-22.335 ± 42.2249-43.969 ± 24.7674
Day 1821-35.062 ± 30.935624.435 ± 178.7882
SecondaryPercent Change In Haptoglobin Levels From Baseline To Day 169 And Day 1821

Baseline was defined as the last non-missing assessment value prior to the first ALXN1210 infusion.

Time frame:
Baseline, Day 169, Day 1821
Reported as:
Mean · percent change
Percent Change In Haptoglobin Levels From Baseline To Day 169 And Day 1821
percent changeALXN1210 Cohort 1ALXN1210 Cohort 2
Day 16940.0000 ± 55.1362017.1429 ± 45.35574
Day 182172.0000 ± 144.8102262.5000 ± 125.00000
SecondaryPercent Change In Reticulocyte/Erythrocyte Count From Baseline To Day 169 And Day 1821

Baseline was defined as the last non-missing assessment value prior to the first ALXN1210 infusion.

Time frame:
Baseline, Day 169, Day 1821
Reported as:
Mean · percent change
Percent Change In Reticulocyte/Erythrocyte Count From Baseline To Day 169 And Day 1821
percent changeALXN1210 Cohort 1ALXN1210 Cohort 2
Day 169-21.203 ± 14.146128.784 ± 54.2636
Day 1821-32.736 ± 18.89979.763 ± 22.5892
SecondaryPercent Change In Paroxysmal Nocturnal Hemoglobinuria (PNH) Red Blood Cell (RBC) Clones From Baseline To Day 169 And Day 1933

Baseline was defined as the last non-missing assessment value prior to the first ALXN1210 infusion.

Time frame:
Baseline, Day 169, Day 1933
Reported as:
Mean · percent change
Percent Change In Paroxysmal Nocturnal Hemoglobinuria (PNH) Red Blood Cell (RBC) Clones From Baseline To Day 169 And Day 1933
percent changeALXN1210 Cohort 1ALXN1210 Cohort 2
Day 1697.873 ± 19.306425.840 ± 62.9677
Day 193315.927 ± 34.879613.960 ± 78.9414
SecondaryPercent Change In D-dimer Levels From Baseline To Day 169 And Day 1821

Baseline was defined as the last non-missing assessment value prior to the first ALXN1210 infusion.

Time frame:
Baseline, Day 169, Day 1821
Reported as:
Mean · percent change
Percent Change In D-dimer Levels From Baseline To Day 169 And Day 1821
percent changeALXN1210 Cohort 1ALXN1210 Cohort 2
Day 169-27.42 ± 40.015-0.49 ± 73.116
Day 1821-12.74 ± 54.82125.15 ± 43.861
SecondaryChange In Clinical Manifestations Of PNH From Baseline To Day 169 And Day 1821

Clinical manifestations are defined as fatigue, abdominal pain, dyspnea, dysphagia, chest pain, and erectile dysfunction (ED) by cohort. Improvement is defined as present at baseline and absent at Day 169 endpoint. Worsening is defined as absent at Baseline and present at Day 169 endpoint.

Time frame:
Baseline, Day 169, Day 1821
Reported as:
Count of participants · Participants
Change In Clinical Manifestations Of PNH From Baseline To Day 169 And Day 1821
ParticipantsALXN1210 Cohort 1ALXN1210 Cohort 2
Fatigue: Day 169 — Improved from Baseline11
Fatigue: Day 169 — Worsened from Baseline00
Fatigue: Day 169 — No Change/Not Applicable56
Fatigue: Day 1821 — Improved from Baseline21
Fatigue: Day 1821 — Worsened from Baseline00
Fatigue: Day 1821 — No Change/Not Applicable33
Abdominal pain: Day 169 — Improved from Baseline03
Abdominal pain: Day 169 — Worsened from Baseline00
Abdominal pain: Day 169 — No Change/Not Applicable64
Abdominal pain: Day 1821 — Improved from Baseline02
Abdominal pain: Day 1821 — Worsened from Baseline00
Abdominal pain: Day 1821 — No Change/Not Applicable52
Dyspnoea: Day 169 — Improved from Baseline21
Dyspnoea: Day 169 — Worsened from Baseline00
Dyspnoea: Day 169 — No Change/Not Applicable46
Dyspnoea: Day 1821 — Improved from Baseline21
Dyspnoea: Day 1821 — Worsened from Baseline00
Dyspnoea: Day 1821 — No Change/Not Applicable33
Dysphagia: Day 169 — Improved from Baseline01
Dysphagia: Day 169 — Worsened from Baseline00
Dysphagia: Day 169 — No Change/Not Applicable66
Dysphagia: Day 1821 — Improved from Baseline00
Dysphagia: Day 1821 — Worsened from Baseline00
Dysphagia: Day 1821 — No Change/Not Applicable54
Chest pain: Day 169 — Improved from Baseline02
Chest pain: Day 169 — Worsened from Baseline00
Chest pain: Day 169 — No Change/Not Applicable65
Chest pain: Day 1821 — Improved from Baseline01
Chest pain: Day 1821 — Worsened from Baseline00
Chest pain: Day 1821 — No Change/Not Applicable53
ED: Day 169 — Improved from Baseline10
ED: Day 169 — Worsened from Baseline00
ED: Day 169 — No Change/Not Applicable57
ED: Day 1821 — Improved from Baseline10
ED: Day 1821 — Worsened from Baseline00
ED: Day 1821 — No Change/Not Applicable31
SecondaryArea Under The Serum Concentration-versus-time-curve From Time 0 (Dosing) To The Last Quantifiable Concentration (AUCt) At Day 1

AUCt reported in hours\*microgram/milliliter (h\*ug/mL).

Time frame:
Day 1
Reported as:
Mean · h*ug/mL
Area Under The Serum Concentration-versus-time-curve From Time 0 (Dosing) To The Last Quantifiable Concentration (AUCt) At Day 1
h*ug/mLALXN1210 Cohort 1ALXN1210 Cohort 2
Area Under The Serum Concentration-versus-time-curve From Time 0 (Dosing) To The Last Quantifiable Concentration (AUCt) At Day 114273.95 ± 4907.43842366.62 ± 3710.120
SecondaryAUCt/ Dose-normalized (D) At Day 1
Time frame:
Day 1
Reported as:
Mean · h*ug/mL/mg
AUCt/ Dose-normalized (D) At Day 1
h*ug/mL/mgALXN1210 Cohort 1ALXN1210 Cohort 2
AUCt/ Dose-normalized (D) At Day 135.68 ± 12.26970.61 ± 6.184
SecondaryArea Under The Serum Concentration-versus-time-curve From Time 0 (Dosing) To The End Of The Dosing Interval (AUCtau) At Day 141
Time frame:
Day 141
Reported as:
Mean · h*ug/mL
Area Under The Serum Concentration-versus-time-curve From Time 0 (Dosing) To The End Of The Dosing Interval (AUCtau) At Day 141
h*ug/mLALXN1210 Cohort 1ALXN1210 Cohort 2
Area Under The Serum Concentration-versus-time-curve From Time 0 (Dosing) To The End Of The Dosing Interval (AUCtau) At Day 141216515.22 ± 68099.982217936.47 ± 31023.979
SecondaryAUCtau/D At Day 141
Time frame:
Day 141
Reported as:
Mean · h*ug/mL/mg
AUCtau/D At Day 141
h*ug/mL/mgALXN1210 Cohort 1ALXN1210 Cohort 2
AUCtau/D At Day 141240.57 ± 75.667242.15 ± 34.471
SecondaryMaximum Observed Serum Concentration (Cmax) At Day 1 And Day 141
Time frame:
Day 1 and Day 141
Reported as:
Mean · ug/mL
Maximum Observed Serum Concentration (Cmax) At Day 1 And Day 141
ug/mLALXN1210 Cohort 1ALXN1210 Cohort 2
Day 1114.00 ± 15.556203.50 ± 10.279
Day 141514.00 ± 147.078512.25 ± 64.958
SecondaryCmax/D At Day 1 And Day 141
Time frame:
Day 1 and Day 141
Reported as:
Mean · ug/mL/mg
Cmax/D At Day 1 And Day 141
ug/mL/mgALXN1210 Cohort 1ALXN1210 Cohort 2
Day 10.29 ± 0.0390.34 ± 0.017
Day 1410.57 ± 0.1630.57 ± 0.072
SecondaryConcentration At The End Of The Dosage Interval (Ctrough) At Day 1 And At Day 141
Time frame:
Day 1 and Day 141
Reported as:
Mean · ug/mL
Concentration At The End Of The Dosage Interval (Ctrough) At Day 1 And At Day 141
ug/mLALXN1210 Cohort 1ALXN1210 Cohort 2
Day 173.25 ± 18.17380.50 ± 6.541
Day 141243.50 ± 126.572204.00 ± 56.586
SecondaryTime To Maximum Observed Serum Concentration (Tmax) At Day 1 And Day 141
Time frame:
Day 1 and Day 141
Reported as:
Mean · h
Time To Maximum Observed Serum Concentration (Tmax) At Day 1 And Day 141
hALXN1210 Cohort 1ALXN1210 Cohort 2
Day 12.38 ± 2.4041.88 ± 0.957
Day 1414.03 ± 0.0352.40 ± 1.124
SecondaryPercent Change In Chicken Red Blood Cell (cRBC) Hemolysis From Baseline To Day 1709
Time frame:
Baseline, Day 1709
Reported as:
Mean · percent change
Percent Change In Chicken Red Blood Cell (cRBC) Hemolysis From Baseline To Day 1709
percent changeALXN1210 Cohort 1ALXN1210 Cohort 2
Percent Change In Chicken Red Blood Cell (cRBC) Hemolysis From Baseline To Day 1709-72.316 ± 19.0919-97.314 ± 3.2298
SecondaryPercent Change In Free Complement Component 5 (C5) Concentration From Baseline To Day 1709
Time frame:
Baseline, Day 1709
Reported as:
Mean · percent change
Percent Change In Free Complement Component 5 (C5) Concentration From Baseline To Day 1709
percent changeALXN1210 Cohort 1ALXN1210 Cohort 2
Percent Change In Free Complement Component 5 (C5) Concentration From Baseline To Day 1709-99.839 ± 0.0130-99.802 ± 0.0950
SecondaryPercent Change In Total C5 Concentration From Baseline To Day 1709
Time frame:
Baseline, Day 1709
Reported as:
Mean · percent change
Percent Change In Total C5 Concentration From Baseline To Day 1709
percent changeALXN1210 Cohort 1ALXN1210 Cohort 2
Percent Change In Total C5 Concentration From Baseline To Day 170965.852 ± 31.205486.676 ± 24.6721
SecondaryParticipants Experiencing Antidrug Antibodies (ADAs)
Time frame:
Day 1821
Reported as:
Count of participants · Participants
Participants Experiencing Antidrug Antibodies (ADAs)
ParticipantsALXN1210 Cohort 1ALXN1210 Cohort 2
Participants Experiencing Antidrug Antibodies (ADAs)00
Post-hocPercent Change In LDH Levels From Baseline To Day 1821

Baseline was defined as the average of all available assessments prior to first ALXN1210 infusion.

Time frame:
Baseline, Day 1821
Reported as:
Mean · percent change
Percent Change In LDH Levels From Baseline To Day 1821
percent changeALXN1210 Cohort 1ALXN1210 Cohort 2
Percent Change In LDH Levels From Baseline To Day 1821-86.244 ± 4.7348-84.413 ± 3.6473

Adverse events

Collected over Day 1 through Day 1957. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ALXN1210 Cohort 10/6 (0%)3/6 (50%)6/6 (100%)
ALXN1210 Cohort 20/7 (0%)4/7 (57.1%)7/7 (100%)
Most frequent serious events
Most frequent serious events
EventALXN1210 Cohort 1ALXN1210 Cohort 2
AnaemiaBlood and lymphatic system disorders0/62/7
Tubo-ovarian abscessInfections and infestations1/60/7
Bile duct stoneHepatobiliary disorders1/60/7
CholangitisHepatobiliary disorders1/60/7
Cholangitis acuteHepatobiliary disorders1/60/7
ContusionInjury, poisoning and procedural complications1/60/7
Meningococcal infectionInfections and infestations0/61/7
Parvovirus infectionInfections and infestations0/61/7
PneumoniaInfections and infestations0/61/7
Cholecystitis acuteHepatobiliary disorders0/61/7
Most frequent other events
Showing 10 of 97
Most frequent other events
EventALXN1210 Cohort 1ALXN1210 Cohort 2
Upper respiratory tract infectionInfections and infestations3/66/7
HeadacheNervous system disorders2/64/7
Abdominal painGastrointestinal disorders3/62/7
PyrexiaGeneral disorders3/60/7
ConstipationGastrointestinal disorders1/63/7
DizzinessNervous system disorders2/60/7
FatigueGeneral disorders2/62/7
Back painMusculoskeletal and connective tissue disorders2/62/7
DiarrhoeaGastrointestinal disorders2/62/7
HordeolumInfections and infestations0/62/7

Baseline characteristics

Age, Continuous
Age, Continuous(years)ALXN1210 Cohort 1ALXN1210 Cohort 2Total
Mean41.1 ± 10.8743.6 ± 13.4842.4 ± 11.91
Sex: Female, Male
Sex: Female, Male(Participants)ALXN1210 Cohort 1ALXN1210 Cohort 2Total
Female257
Male426
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)ALXN1210 Cohort 1ALXN1210 Cohort 2Total
Asian6612
White011
08

Study locations

8 sites
  • Clinical Trial Site
    Liverpool, New South Wales 2170, Australia
  • Clinical Trial Site
    Woolloongabba, Queensland 4102, Australia
  • Clinical Trial Site
    Seoul, 03080, Korea, Republic of
  • Clinical Trial Site
    Seoul, 03722, Korea, Republic of
  • Clinical Trial Site
    Seoul, 05505, Korea, Republic of
  • Clinical Trial Site
    Seoul, 06351, Korea, Republic of
  • Clinical Trial Site
    Seoul, 06951, Korea, Republic of
  • Clinical Trial Site
    Ulsan, 44033, Korea, Republic of
09

References and documents

Publications

  • Roth A, Rottinghaus ST, Hill A, Bachman ES, Kim JS, Schrezenmeier H, Terriou L, Urbano-Ispizua A, Wells RA, Jang JH, Kulasekararaj AG, Szer J, Aguzzi R, Damokosh AI, Shafner L, Lee JW. Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies. Blood Adv. 2018 Sep 11;2(17):2176-2185. doi: 10.1182/bloodadvances.2018020644. PubMed 30171081 ↗

Individual participant data

Plan to share: Yes — Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.

Supporting information: Study protocol, Clinical study report

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2015 to primary completion in Jul 2016, 8 months.

Results were first posted in Jan 2018, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2015
First posted
Nov 6, 2015
StartActual
Nov 12, 2015
Primary completionActual
Jul 14, 2016
CompletionActual
Mar 11, 2021
Results first posted
Jan 30, 2018
Last update
May 16, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02598583
Responsible party
Sponsor
First posted
Nov 6, 2015
Start date
Nov 12, 2015
Primary completion
Jul 14, 2016
Completion
Mar 11, 2021
Results posted
Jan 30, 2018
Last update
May 16, 2022

Study contacts

Alexion Pharmaceuticals, Inc.
study director · Alexion Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ravulizumab

Start the discussion